Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | TK1 | P04183 | 4/20 | 0.47 |
| ▸ | TK2 | O00142 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26273448 | 1.00 | LMNA (0.63) | LMNASMN1; SMN2RNASE1ALOX12ADRA1A | |
| SCHEMBL25372583 | 1.00 | LMNA (0.63) | LMNASMN1; SMN2RNASE1ALOX12ADRA1A | |
| SCHEMBL9318488 | 1.00 | LMNA (0.63) | LMNASMN1; SMN2RNASE1ALOX12ADRA1A | |
| SCHEMBL25372066 | 0.89 | TOP2A (0.52) | LMNASMN1; SMN2TK1 | |
| SCHEMBL2056757 | 0.89 | RNASE1 (0.62) | LMNARNASE1TK1TK2 | |
| SCHEMBL24059145 | 0.89 | RNASE1 (0.62) | LMNARNASE1TK1TK2 | |
| SCHEMBL24059196 | 0.89 | RNASE1 (0.62) | LMNARNASE1TK1TK2 | |
| SCHEMBL15354282 | 0.89 | RNASE1 (0.62) | LMNARNASE1TK1TK2 | |
| SCHEMBL733403 | 0.89 | RNASE1 (0.62) | LMNARNASE1TK1TK2 | |
| SCHEMBL25747162 | 0.89 | RNASE1 (0.62) | LMNARNASE1TK1TK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145654-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. | 2025-05-08 | — | — | US | disclosed |
| EP-4493573-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | Rome Therapeutics, Inc. (US) | 2025-01-22 | — | — | EP | disclosed |
| US-12187758-B2 | Compounds and methods for treating disease | ROME THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| WO-2024103016-A1 | 4'-HALOMETHYL-CYTIDINE PHOSPHORAMIDATES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | ROME THERAPEUTICS, INC. (US) | 2024-05-16 | — | — | WO | disclosed |
| US-20240043467-A1 | 5'-SUBSTITUTED NUCLEOSIDE MONOPHOSPHATES, PRODRUGS THEREOF, AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2024-02-08 | — | — | US | disclosed |
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| WO-2023178133-A9 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS INC (US) | 2023-09-21 | — | — | US | disclosed |
| WO-2023178133-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| EP-4204428-A1 | 5'-SUBSTITUTED NUCLEOSIDE MONOPHOSPHATES, PRODRUGS THEREOF, AND USES RELATED THERETO | Emory University (US) | 2023-07-05 | — | — | EP | disclosed |
| WO-2022047400-A1 | 5'-SUBSTITUTED NUCLEOSIDE MONOPHOSPHATES, PRODRUGS THEREOF, AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2022-03-03 | — | — | WO | disclosed |
| CN-104640444-B | Dual liver-targeting phosphoramidate and phosphoramidate prodrugs | 河南美泰宝生物制药有限公司 | 2016-12-14 | — | — | CN | disclosed |
| US-9156874-B2 | Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs | NANJING MOLECULAR RESEARCH, INC. (CN) | 2015-10-13 | — | — | US | disclosed |
| CN-104640444-A | Dual liver-targeting phosphoramidate and phosphoramidate prodrugs | NANJING MOLECULAR RES INC | 2015-05-20 | — | — | CN | disclosed |
| US-20130210757-A1 | DOUBLE-LIVER-TARGETING PHOSPHORAMIDATE AND PHOSPHONOAMIDATE PRODRUGS | NANJING MOLECULAR RESEARCH, INC. (CN) | 2013-08-15 | — | — | US | disclosed |
| EP-0605582-A1 | PHOSPHORAMIDATE ANALOGS OF 5-FLUORO-2'-DEOXYURIDINE | THE UNIVERSITY OF ROCHESTER (US) | 1994-07-13 | — | — | EP | disclosed |
| US-5302707-A | 5-fluorouridine nucleoside phosphate compounds | AFFYMAX TECHNOLOGIES N.V. (US) | 1994-04-12 | — | — | US | disclosed |
| US-5233031-A | Antitumor, anticarcinogenic agents | UNIVERSITY OF ROCHESTER (US) | 1993-08-03 | — | — | US | disclosed |
| WO-1993006120-A1 | PHOSPHORAMIDATE ANALOGS OF 5-FLUORO-2'-DEOXYURIDINE | UNIVERSITY OF ROCHESTER (US) | 1993-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | LMNA 2032/4885SMN1; SMN2 152/4885RNASE1 3/4885 |
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | LMNA 2032/4885SMN1; SMN2 152/4885RNASE1 3/4885 |
| US-20130210757-A1 | DOUBLE-LIVER-TARGETING PHOSPHORAMIDATE AND PHOSPHONOAMIDATE PRODRUGS | PNP, PAICS, NTPCR | LMNA 1668/4885SMN1; SMN2 2552/4885RNASE1 141/4885 |
| US-20240043467-A1 | 5'-SUBSTITUTED NUCLEOSIDE MONOPHOSPHATES, PRODRUGS THEREOF, AND USES RELATED THERETO | PNP, ENTPD5, TYMP | LMNA 3158/4885SMN1; SMN2 4446/4885RNASE1 104/4885 |
| US-20250145654-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | LMNA 2032/4885SMN1; SMN2 152/4885RNASE1 3/4885 |
| US-12187758-B2 | Compounds and methods for treating disease | EHMT1, POLRMT, RNASE1 | LMNA 2032/4885SMN1; SMN2 152/4885RNASE1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.